Researcher Database

（Last updated : 2025-02-26 12:25:33）　

Visruth.jpg not found

SHIMOZUMA Kojiro

Department / Course Research Organization of Science and Technology

Title / Position Professor

Other Affiliations
1.	Graduate School of Life Sciences
2.	Research Organization of Open Innovation & Collaboration Research Center for Medical and Long-Term Care Management
3.	Research Organization of Science and Technology

Academic background
1.		│ Osaka University Ph.D. in Medical Science
2.	～1981/03	Department of Medicine │ Faculty of Medicine │ Yamaguchi University │ Graduated
3.	～1985/03	Doctorial Course │ Graduate School of Medicine │ Osaka University Graduate School of Medicine │ Completed

Business career
1.	1997/05 ～ 1997/11	Visiting researcher │ Div. of Cancer Prevention and Control Res., Jonsson Comprehensive Cancer Center, │ UCLA

Research activities
1.		American Society of Clinical Oncology (ASCO)
2.		International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
3.	2015/01/01 ～ 2016/12/31	∟ President (Japan chapter)
4.		International Society for Quality of Life Research (ISOQOL)
5.	2019/10/01 ～	∟ Chair (Japan SIG)
Display All（18）

Subject of research
1.	Development of the systems which can allocate healthcare resources efficiently and fairly.
2.	Basic research for health outcomes assessment and pharmaco economics
3.	Health outcomes, cost-effectiveness, and cost-utility of various healthcare interventions

Research summary
Development of the systems which can allocate healthcare resources efficiently and fairly. =Research theme= 1. Basic and applied research for Patient-reported outcomes (PROs). 2. Basic and applied research for healthcare economic assessments. 3. Development of the systems of the healthcare resource allocation based on the various viewpoints (Multi-Criteria Decision Analysis: MCDA)

Present specialized field
Medical pharmacy, Medical Sociology, Epidemiology and preventive medicine, Hygiene and public health, Medical and hospital management, General Surgery, Digestive surgery (Keyword：health services research, health outcomes research, pharmacoeconomics, clinical oncology, palliative medicine)

Books
1.	2017/09	The Ethics of health care rationing - An introduction │ ,pp.97-143
2.	2017/07	Methods for the Economic Evaluation of Health Care Programmes (Fourth Edition) │ ,pp.143-207
3.	2017/02	CANCER BOARD OF THE BREAST・patient-reported outcome measures (PROMs) │ ,pp.59
4.	2015/03	Examination and diagnosis of obstetrics and gynaecology: gynecological oncology - D. Assessments and adverse events in oncology treatment 9. Quality of life assessments │ ,pp.246-249
5.	2015/02	Kidney Cancer No.3 Topics 'Assessments of patients' 'subjective' health outcomes and their applications to clinical practices' │ ,pp.16-17
Display All（9）

Papers
1.	2025/01/01	Multicenter, open-label, randomized, controlled study to thest the utility of electronic patient-reported outcome monitoring in patients with unresectabel advanced cancers or metastatic/recurrent solid tumors │ Jpn J Clin Oncol │ ,pp.1-9
2.	2024/12/01	Scoping review of cost-effectiveness analysis of pharmacotherapy for painful diabetic neuropathy - impications for studies in Japan │ Japanese Journal of Pharmaceutical and Diabetes │ ,pp.110-125
3.	2024/08	Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial │ eClinicalMedicine │ 74,pp.102715
4.	2024/03	Cost-effectiveness Analysis of Nivolumab Plus ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan │ Value Helaht Reg Issues │ 40,pp.118-126
5.	2024/03	How to select and understand guidelines for patient‑reported outcomes: a scoping review of existing guidance │ BMC Health Services Research │ 24,pp.335
Display All（115）

Academic conference presentation
1.	2022/05	Cost effectiveness analysis of nivolumab plus chemotherapy VS chemotherapy in patients with advanced gastric cancer in Japan.
2.	2021/11/30	Cost-effectiveness analysis of nivolumab plus ipilimumab therapy as first-line therapy in advanced non-small-cell lung cancer in Japan
3.	2021/11/30	Cost-effectiveness of preventive intervention for prediabetes in Japan
4.	2021/11/30	Economic evaluation of nivolumab plus ipilimumab in advanced renal-cell carcinoma in Japan
5.	2019/11/04	Relationship Between Partial Values and Scoring Scale for Each Criterion of the EVIDEM 10th Edition Core Model in Japan.
Display All（32）

Message
1.	Developing the reliable and convincing health care systems By assessing 'health care quality' not only from individual point of view but also from societal point of view, we are trying to develop more reliable and convincing health care systems.

E-Mail Address